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Aims
To evaluate the long-term efficacy of triptorelin 3.75 mg
subcutaneously injection every 6 weeks on final height
in girls with idiopathic central precocious puberty.
Methods
Forty females with ICPP received triptorelin 3.75 mg
every 6 weeks subcutaneously injection in our hospital
from 2002 to December 2010 and reached final height
were collected. These patients were divided into two
groups according to whether there was presence of
growth deceleration and rhGH used concomitantly dur-
ing the treatment. Group A: triptorelin alone, n=17;
group B: triptorelin + rhGH, n=23. During the treat-
ment, height, weight, annual GV, sexual development,
PAH and adverse effects were observed. BA and height
SDS were monitored yearly. After discontinuation of
treatment, follow-up was continued for 4~9 years till
final height was attained, and age of menarche, time of
menarche from discontinuation were recorded.
Results
FAHs were 159.81±4.95 cm and 161.01±4.89 cm respec-
tively in the two groups, exceed the genetic target height
(THt), about the 50th percentile of normal female
height. FAH increased by 1.51±4.30 cm, 4.86±4.49 cm
from THt respectively. The values of (FAH-THt)
showed significant difference between the two groups
(p<0.05). FAH was less than the predicted adult height
(PAH) before and after treatment in group A, and
greater than that of group B. The value of (FAH-PAH
post-treatment) showed significant difference between
the two groups (p<0.05). FAH was positively correlated
with Ht SDS-BA at the end of treatment, THt, course of
rhGH treatment and age of menarche (r2=0.66). BMI
increased after treatment compared with that before
treatment in both groups, however, compared with
healthy children at the same age, there was no signifi-
cant tendency of increase. Ages of menarche were
11.74±0.66 years and 12.18±0.69 years respectively.
Times of menarche from discontinuation were
17.41±6.96 months and 14.71±4.77 months respectively.
Conclusion
The final adult height in patients with ICPP was
improved effectively by triptorelin 3.75 mg subcuta-
neously injection every 6 weeks, and more height gain
will be achieved when rhGH was used concomitantly to
refrain from growth deceleration during the treatment.
BMI maintained steadily and ovarian function restored
quickly after discontinuation of the treatment with the
age of menarche similar to that of normal children.
Neither significant adverse effect nor polycystic ovary
syndrome was observed.
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